One Biosciences

One Biosciences is a techbio company that brings AI-powered single-cell analysis into clinical practice, turning routine cancer biopsies into reports that deliver insights in less than two weeks. Created in 2020 after work at Institut Curie showed that standard microfluidic single-cell workflows failed on limited patient biopsies, the company built a platform that delivers high-quality single-cell profiling across tumor types from clinical samples. One Biosciences partners with pharma, biotech, and clinicians to accelerate precision oncology, combining optimized sample preparation, single-cell profiling, and clinically trained AI foundation models. Its OneMap platform is designed to help clinicians and drug developers understand the tumor heterogeneity that drives cancer treatment decisions.